Clinical Trials Logo

Cutaneous Neurofibromas clinical trials

View clinical trials related to Cutaneous Neurofibromas.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT00865644 Completed - Clinical trials for Neurofibromatosis Type 1

Topical Imiquimod 5% Cream for Treatment of Cutaneous Neurofibromas in Adults With Neurofibromatosis 1

Start date: March 2009
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine if imiquimod cream can reverse the growth of neurofibromas. Imiquimod is a skin cream that works by stimulating the body's immune system to respond to tumors. Imiquimod cream is approved for use in patients with various skin lesions, including actinic keratosis, superficial basal cell carcinoma, and external genital warts. Information from these studies, as well as previous laboratory studies, suggest that imiquimod cream may help shrink neurofibromas or keep them from growing.

NCT ID: NCT00657202 Completed - Clinical trials for Neurofibromatosis Type 1

Ranibizumab for Neurofibromas Associated With Neurofibromatosis 1

Start date: March 2008
Phase: Phase 0
Study type: Interventional

The purpose of this research study is to determine if ranibizumab can prevent the growth of neurofibromas. We will also be collecting extra blood and serum samples to help us learn more about NF1. Ranibizumab is a drug that affects the development of blood vessels that feed tumors. It targets a substance in the body called VEGF (Vascular Endothelial Growth Factor). VEGF helps tumors to grow and survive by supporting the growth of blood vessels that bring nutrients to the tumor. VEGF is made by cancerous tumors and also by non-cancerous tumors such as neurofibromas.